What Hyperici Extract Siccum Treats: Main Uses and Benefits

---

The primary therapeutic domain of St. John's wort dry extract is its use in situations involving certain distressing symptoms of the emotional sphere. The product is generally considered relevant for managing mild to moderate depressive episodes.

This herbal medicine may be part of symptomatic management for mild depressive episodes and persistent low spirits, along with associated symptom clusters like nervousness, inner restlessness, and mood-related sleep disturbances. The extract is applied in contexts marked by increased discomfort or tension, supporting the patient during difficult episodes by easing distress related to emotional imbalance. “It is used for managing symptom clusters that may become disruptive and interfere with daily comfort.” This supportive relief contributes to improved day-to-day comfort and supports the patient's emotional well-being, and may assist in supporting a more restful sleep pattern, which can support general well-being during symptomatic phases.

Quick Fact: Relief for Mood-Related Symptoms
Main Use: Supportive management of mild depressive episodes and associated nervous tension.
Symptom Focus: Low spirits, inner restlessness, and difficulty sleeping linked to mood.
Benefit: Contributes to improved day-to-day comfort and emotional well-being.

Regulatory References

1. European Union herbal monograph on Hypericum perforatum L., herba (Well-established use)

Who Can and Cannot Use Hyperici extractum siccum

The eligibility for St. John's wort dry extract is defined by specific regulatory criteria concerning age, reproductive status, and certain health conditions or activities. Official labeling indicates that use is permitted for adults and older adults for the symptomatic relief of slightly low mood.

---

Populations That Must Not Use the Extract (Contraindications)

Use is formally contraindicated in patients with a known history of dermal photosensitivity or those who are undergoing phototherapy or any intensive UV light exposure, including the use of sunbeds or solariums. The product is also contraindicated for individuals with known hypersensitivity to Hypericum perforatum or any of its excipients.

---

Populations Where Use is Not Recommended

Use is not recommended in children and adolescents under 18 years of age because official data are insufficient to establish safety and efficacy in this age group. Additionally, the extract is not recommended for women who are pregnant or breastfeeding due to a lack of sufficient safety data concerning the developing fetus or infant. A specific restriction also applies to patients: the product is not recommended in the 10 days leading up to a scheduled surgical procedure.

The dry extract of St. John's wort (Hyperici extract siccum) has a well-documented and clinically significant potential for drug-drug interactions, which are formally classified in regulatory documents.

Pharmacokinetic Induction and Contraindications

The primary interaction is a pharmacokinetic (PK) induction effect. The extract is documented as a potent inducer of the metabolic enzymes CYP3A4, CYP2C9, and CYP2C19, as well as the efflux transporter P-glycoprotein (P-gp). This induction accelerates the breakdown and clearance of many co-administered medicines, leading to their reduced plasma concentrations and a resulting risk of therapeutic failure.

This outcome necessitates contraindicated combination status for several critical drug classes, including Immunosuppressants (e.g., Ciclosporin, Tacrolimus), many Antiretrovirals, Anticoagulants (e.g., Warfarin), and Oral Contraceptives. Co-administration of these medicines is officially prohibited.

Pharmacodynamic Risk

The second interaction type is pharmacodynamic (PD). Regulatory documents cite an additive risk of Serotonin Syndrome when the extract is combined with other serotonergic agents, such as certain Antidepressants (SSRIs/SNRIs) and Triptans. This combination is also subject to regulatory restriction.

Patients discontinuing Hyperici extract siccum must be monitored, as the reversal of enzyme induction can cause the plasma levels of interacting drugs to rise.

How Hyperici extract siccum Works

---

The mechanism of dry Hypericum perforatum extract is polyvalent, acting simultaneously on multiple central nervous system (CNS) targets. The primary active component, hyperforin, functions as a broad-spectrum inhibitor of neurotransmitter reuptake. This action blocks the presynaptic clearance of serotonin, norepinephrine, dopamine, and amino acids like GABA and L-Glutamate from the synaptic cleft. This crucial molecular event results in a sustained increase in the effective concentration of these transmitters, contributing to increased signal transmission within neural circuits governing affect.

Beyond reuptake inhibition, the extract influences neuronal excitability by activating Transient Receptor Potential ( TRPC6) channels and modulates the Hypothalamic-Pituitary-Adrenal (HPA) axis regulatory loop. This combined action influences the signaling patterns associated with stress and promotes a more functionally regulated state in the affected neural systems. The overall efficacy is attributed to the synergy of these mechanisms; however, the level of pathway modulation is physiologically constrained, limiting its functional influence in severe states.

The administration of Hyperici extract siccum is based entirely on the oral route, utilizing solid dosage forms such as capsules or coated tablets that contain the standardized dry extract. The extract's use is formalized by specific instructions that dictate the required daily dose and frequency.

Total daily dosage for the dry extract typically falls within the range of 600 mg to 1800 mg, depending on the product’s specific concentration and standardization. This dose may be administered once daily or as divided use (two or three times per day) to reach the required daily total. For proper intake, the tablets or capsules are directed to be swallowed whole with liquid and must not be chewed.

Usage of the extract is generally categorized as short-term. If the condition remains unchanged after a duration of 4 to 6 weeks, the protocol requires a professional reassessment of the ongoing administration. Standard adult dosing is applied to older adults, as no adjustment is officially mandated. Furthermore, the product is not recommended for use by children and adolescents under 18 years of age.

Research Evidence / Overview of Studies for Hyperici extract siccum

---

Evidence for use in Mild to Moderate Low Spirits

The research for dry extract of St. John’s wort primarily involves extensive clinical investigation using Randomized Controlled Trials (RCTs). In these trials, participants with symptoms of mild to moderate low spirits were monitored over defined time intervals, often comparing the extract to either an inactive placebo or to predefined control substances. Studies have focused mainly on adult populations monitored during these defined time intervals.

Research examined outcomes related to core symptoms of mild to moderate depression, often using established clinical rating scales, such as the Hamilton Rating Scale for Depression (HAM-D), to measure changes from the start of the study. Findings describe patterns observed in these studies where the measured outcomes reached criteria for defined clinical response thresholds in observed populations. The results from these individual trials have been compiled into numerous Systematic Reviews and Meta-analyses, which contribute context to the documented patterns within the broader evidence landscape. The volume of documented research for this specific symptom severity level is substantial, and regulatory review of this data landscape resulted in the assignment of 'well-established medicinal substance' status.

---

Long-Term Studies and Follow-up

The vast majority of controlled trials examining initial symptom change have been short-term, typically observing responses over defined time intervals of four to eight weeks. These short durations are relevant in trials assessing acute or episodic symptom patterns, but they offer limited information about sustained use.

Some longer-term studies have been conducted, with certain trials monitoring patients for continuation and maintenance treatment for up to six months or even one year. Findings suggest that the follow-up durations for many clinical questions, especially concerning long-term use and maintenance, remain limited compared to the potential chronic nature of conditions characterized by cycles of stability and flare-ups.

---

Evidence in Special Populations and Research Gaps

Trial evaluation has been limited for several groups outside of the main adult population. For instance, data for children and adolescents are generally insufficient, and this extract has not been the focus of extensive trial evaluation for those under the age of 18. Similarly, research describing the outcomes in older adults or in populations with various comorbid conditions is not as extensive or conclusive as the research available for the main adult group. Research has generally not been conducted in cohorts of pregnant or lactating women, and official guidance accounts for the lack of specific evidence in these populations.

A primary concern in the evidence base is the variability across studies, where different extracts and standardization methods were used, making direct comparisons and generalizations challenging. Furthermore, studies documented inconsistent measured outcomes when the focus shifts to individuals with severe depressive episodes or major depressive disorder. For these more acute or severe conditions, the evidence is limited.

How to Store and Dispose of Hyperici extract siccum

This information reflects the required storage and disposal instructions found in official regulatory labeling for St. John's Wort dry extract.

Storage Requirements

• Temperature: Do not store the medicine above 25 C (77 F).
• Environmental Protection: The product must be stored in its original, tightly closed container to protect it from exposure to light and moisture.
• Child Safety: Always keep the medicine out of the sight and reach of children.
• Stability: The required storage conditions must be maintained to ensure the product remains stable until its stated expiration date.

Disposal Instructions

To dispose of expired or unused Hyperici extract siccum, follow local and national regulations. Do not dispose of the medicine in household trash or down the drain (toilet or sink). Unused medicines should be returned to a pharmacy or an approved collection point for safe pharmaceutical waste disposal.